Want to see FR:ABVX full AI Analyst Report?
ABVX Stock Chart & Stats
€99.95
-€1.20(-1.06%)
At close: 4:00 PM EDT
€99.95
-€1.20(-1.06%)
Day’s Range― - ―
52-Week Range€60.45 - €139.00
Previous CloseN/A
Volume27.27K
Average Volume (3M)126.38K
Market Cap
€7.29B
Enterprise Value€8.80B
Total Cash (Recent Filing)€410.68M
Total Debt (Recent Filing)€1.21M
Price to Earnings (P/E)―
Beta1.36
Next Earnings
Dec 14, 2026EPS Estimate
-0.81Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.71
Shares Outstanding87,548,100
10 Day Avg. Volume108,329
30 Day Avg. Volume126,375
Financial Highlights & Ratios
PEG Ratio-0.34
Price to Book (P/B)18.39
Price to Sales (P/S)0.00
P/FCF Ratio-51.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€131.00Price Target Upside31.07% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-3.67
Revenue Forecast (FY)€4.21M
Bulls Say, Bears Say
Bulls Say
Focused Clinical PipelineA focused pipeline addressing chronic inflammatory diseases gives Abivax a clear therapeutic strategy and potential platform for multiple indications. Lead-program concentration can support efficient development expertise and create durable upside if obefazimod demonstrates clinical and commercial value.
Improved Balance SheetThe materially stronger 2025 balance sheet and low leverage provide greater financial flexibility than in prior periods. Higher equity and limited debt can extend operating runway and reduce near-term balance-sheet pressure while the company advances its clinical programs.
Strong Historical Gross MarginNear-100% historical gross margins indicate that the business model can retain substantial value from revenue once commercial activity is established. If revenue returns at meaningful scale, this economics profile could provide operating leverage against the company’s substantial research and development cost base.
Bears Say
Deepening LossesLarge and widening net and operating losses show that current activities are not yet supported by internally generated earnings. Persistent losses consume equity and increase the financing required to sustain clinical development, making future profitability dependent on successful pipeline progress and commercialization.
Unstable Revenue BaseThe fall to zero revenue in 2025 demonstrates that Abivax lacks a dependable commercial revenue stream during the period covered. This weakens visibility into future operating performance and leaves the company reliant on clinical milestones and external capital rather than recurring product sales.
Persistent Cash BurnRecurring negative operating and free cash flow indicates that the company remains far from self-funding its operations and research programs. The approximately -162M 2025 free cash flow reinforces dependence on external financing, which can constrain strategic flexibility and create dilution or refinancing pressure.
Abivax SA News
ABVX FAQ
What was Abivax SA’s price range in the past 12 months?
Abivax SA lowest stock price was €60.45 and its highest was €139.00 in the past 12 months.
What is Abivax SA’s market cap?
Abivax SA’s market cap is €7.29B.
When is Abivax SA’s upcoming earnings report date?
Abivax SA’s upcoming earnings report date is Dec 14, 2026 which is in 52 days.
How were Abivax SA’s earnings last quarter?
Abivax SA released its earnings results on Sep 21, 2026. The company reported -€1.47 earnings per share for the quarter, missing the consensus estimate of -€0.801 by -€0.669.
Is Abivax SA overvalued?
According to Wall Street analysts Abivax SA’s price is currently Undervalued.
Does Abivax SA pay dividends?
Abivax SA does not currently pay dividends.
What is Abivax SA’s EPS estimate?
Abivax SA’s EPS estimate is -0.81.
How many shares outstanding does Abivax SA have?
Abivax SA has 87,548,100 shares outstanding.
What happened to Abivax SA’s price movement after its last earnings report?
Abivax SA reported an EPS of -€1.47 in its last earnings report, missing expectations of -€0.801. Following the earnings report the stock price went down -4.688%.
Which hedge fund is a major shareholder of Abivax SA?
Currently, no hedge funds are holding shares in FR:ABVX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Abivax SA
Abivax S.A. is a Paris-based pharmaceutical firm, established in 2013, dedicated to identifying and refining treatments for various serious conditions, including inflammatory and infectious diseases, as well as cancer. Its primary drug candidate, ABX464, is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's disease, and COVID-19, and is in Phase IIa trials for rheumatoid arthritis. This compound has also successfully completed a Phase IIa study focused on achieving viral remission in HIV patients. Additionally, the company is advancing ABX 196, an immune-enhancing agent, through Phase 1/2 clinical trials for hepatocellular cancer. Beyond these main programs, Abivax is also engaged in research initiatives targeting Dengue fever, influenza, and the respiratory syncytial virus. The company holds significant licensing agreements with esteemed institutions such as the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie.
ABVX Stock 12 Month Forecast
Average Price Target
€131.00
▲(31.07% Upside)